OOIR: Observatory of International Research

Papers

(The H4-Index of Pharmacological Reviews is 40. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Endothelial Dysfunction in Atherosclerotic Cardiovascular Diseases and Beyond: From Mechanism to Pharmacotherapies	482
Structure, Function, and Pharmacology of Glutamate Receptor Ion Channels	322
Rescuing the Last-Line Polymyxins: Achievements and Challenges	217
Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development	187
International Union of Basic and Clinical Pharmacology. CX. Classification of Receptors for 5-hydroxytryptamine; Pharmacology and Function	165
Acylcarnitines: Nomenclature, Biomarkers, Therapeutic Potential, Drug Targets, and Clinical Trials	165
Subcellular Organization of the cAMP Signaling Pathway	164
Matrix Metalloproteinases: From Molecular Mechanisms to Physiology, Pathophysiology, and Pharmacology	134
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms	125
Therapeutic Targeting of the Complement System: From Rare Diseases to Pandemics	107
Post-Translational Modifications of G Protein–Coupled Receptors Control Cellular Signaling Dynamics in Space and Time	101
Pharmacological Inhibition of the Nod-Like Receptor Family Pyrin Domain Containing 3 Inflammasome with MCC950	98
Sex- and Gender-Based Pharmacological Response to Drugs	97
Dopamine, Immunity, and Disease	92
International Union of Basic and Clinical Pharmacology. CXII: Adenosine Receptors: A Further Update	86
Structure-Based Virtual Screening for Ligands of G Protein–Coupled Receptors: What Can Molecular Docking Do for You?	84
Sex Differences in Opioid and Psychostimulant Craving and Relapse: A Critical Review	77
Mutations in G Protein–Coupled Receptors: Mechanisms, Pathophysiology and Potential Therapeutic Approaches	74
Ontogeny of Hepatic Transporters and Drug-Metabolizing Enzymes in Humans and in Nonclinical Species	74
Aldo-Keto Reductases and Cancer Drug Resistance	72
Unlocking G-Quadruplexes as Antiviral Targets	69
Animal Models of Drug Relapse and Craving after Voluntary Abstinence: A Review	66
E1 Enzymes as Therapeutic Targets in Cancer	62
Hydroxynorketamines: Pharmacology and Potential Therapeutic Applications	60
Inhaled Medicines: Past, Present, and Future	56

Interaction of Cardiovascular Nonmodifiable Risk Factors, Comorbidities and Comedications With Ischemia/Reperfusion Injury and Cardioprotection by Pharmacological Treatments and Ischemic Conditioning	53
ATP and Adenosine Metabolism in Cancer: Exploitation for Therapeutic Gain	53
Aiding and Abetting Anhedonia: Impact of Inflammation on the Brain and Pharmacological Implications	50
Neurobiological Mechanisms of Nicotine Reward and Aversion	50
Therapeutics in the Pipeline Targetingα-Synuclein for Parkinson's Disease	48
Therapeutic Targeting of α7 Nicotinic Acetylcholine Receptors	46
Pharmacological Inhibition of the NLRP3 Inflammasome: Structure, Molecular Activation, and Inhibitor-NLRP3 Interaction	46
Sex/Gender Differences in the Time-Course for the Development of Substance Use Disorder: A Focus on the Telescoping Effect	44
The Angiotensin AT₂Receptor: From a Binding Site to a Novel Therapeutic Target	43
Nonantimicrobial Actions of Macrolides: Overview and Perspectives for Future Development	43
Pharmacological Manipulation of Translation as a Therapeutic Target for Chronic Pain	42
Gαs–Protein Kinase A (PKA) Pathway Signalopathies: The Emerging Genetic Landscape and Therapeutic Potential of Human Diseases Driven by Aberrant Gαs-PKA Signaling	42
The Molecular Biology of Phosphodiesterase 4 Enzymes as Pharmacological Targets: An Interplay of Isoforms, Conformational States, and Inhibitors	42
Goods and Bads of the Endocannabinoid System as a Therapeutic Target: Lessons Learned after 30 Years	40
The Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein	40
Cathepsin B Gene Knockout Improves Behavioral Deficits and Reduces Pathology in Models of Neurologic Disorders	40